Objectives: The replication defect of hepatitis B virus (HBV) lamivudine-resistant mutants can be restored by the development of compensatory mutations. Such mutations have long been recognized for the rtM204V mutant, while little is known about any compensatory mutation specific to the rtM204I mutant. The aim of this study was to search for previously unrecognized compensatory mutations following development of lamivudine-resistant mutants.
Introduction
Chronic hepatitis B virus (HBV) infection is a global health problem, which can lead to severe liver diseases such as cirrhosis and hepatocellular carcinoma. 1, 2 Lamivudine is a nucleoside analogue with potent inhibitory effect on HBV RNA-dependent DNA polymerase. It has been approved for anti-HBV therapy since 1998. 3 Owing to the long half-life of covalently closed circular DNA in infected hepatocytes, rapid recovery of HBV replication occurs after withdrawal of lamivudine. Prolonged use of lamivudine was therefore proposed to maintain sustained viral suppression and thus prevent hepatitis exacerbations. As a result, hepatitis B e antigen (HBeAg) seroconversion is achieved, liver histology is improved and progression to liver cirrhosis is deferred. 4 Unfortunately, the therapeutic effect is drastically compromised by the emergence of lamivudine-resistant mutants after prolonged therapy. 5, 6 Despite a high resistance rate and the approval of other more effective oral antiviral agents (such as entecavir and telbivudine), lamivudine remains widely used in the third world countries owing to its lower cost, fast-acting effect and absence of long-term adverse reaction.
HBV replicates by use of an error-prone viral reverse transcriptase, resulting in a large pool of mutant quasispecies. Drug-resistant mutants selected from this pool of viruses confer replication advantage and, over a period of time, become the dominant strains. 7 The percentage of lamivudine resistance increases progressively during the course of treatment at an annual accumulation rate of 14% -32%, and more than 80% of patients become lamivudine resistant after 48 months of treatment. 8 The major amino acid substitutions associated with lamivudine resistance have been mapped to the YMDD motif in the catalytic domain (C domain) of HBV polymerase, namely rtM204I/V. 8 Usually, these primary mutants have 'less viral fitness', implying they do not replicate as well as the wildtype viruses. 9 Continuous administration of antiviral agents leads to the development of 'compensatory' or 'secondary' mutations that can partially or completely restore replication efficiency. For example, rtL80I, rtL180M and rtV173L can increase the replication efficiency of rtM204V mutants and thus were considered compensatory mutations for rtM204V. 8, 10 On the other hand, little is known about any compensatory mutation for the rtM204I mutant.
In this study, we investigated whether there were other unrecognized compensatory mutations that developed after the initial emergence of YMDD-motif mutations. Serial serum samples collected from patients with rtM204I/V mutants were analyzed. Site-directed mutagenesis experiments were conducted to determine whether the identified mutations were responsible for lamivudine resistance or for restoration of viral replication efficiency.
Patients and methods

Patients
This study was approved by Institutional Review Board, Chang Gung Medical Center. From July 2005 to August 2006, 83 lamivudine-resistant patients carrying YMDD-motif mutations were enrolled. Under written informed consent, serial serum samples were collected for this study. These patients were followed at the Liver Clinic of Chang Gung Memorial Hospital, and during the study period lamivudine monotherapy was given continuously. The rtM204I mutant was detected in 49 patients, and the rtM204V mutant was detected in 34 patients. All the patients were seropositive for hepatitis B virus surface antigen (HBsAg) but seronegative for anti-hepatitis C virus core antibody, anti-hepatitis D virus or anti-HIV antibody. All haemograms and biochemical tests were performed in the clinical pathology laboratories of Chang Gung Memorial Hospital. Serial serum samples were collected and stored at 2708C until use.
Serological assays and HBV DNA assay
HBsAg, antibodies to hepatitis D virus, HBeAg and its antibody (anti-HBe) were assayed using commercially available radioimmunoassay kits HAVABM, CORABM, Ausria II and anti-delta (Abbott Laboratories, North Chicago, IL, USA) and HBeAg/anti-HBe test (Diasorin, Saluggia, Italy). Antibodies to hepatitis C virus and antibodies to anti-HIV were assayed using third-generation enzyme immunoassay kits AxSYM HCV Version 3.0 and AxSYM HIV 1/2 gO Assay, (Abbott Laboratories). Serum HBV DNA levels were quantified using a COBAS TaqMan HBV test (Roche Molecular Systems, Inc., Pleasanton, CA, USA) with a detection limit of 68 copies/mL.
Extraction of HBV DNA and PCR
Serum (100 mL) was mixed with 300 mL of buffer (13.3 mM Tris-HCl, pH 8.0, 6.7 mM EDTA, 0.67% SDS and 133 mg/mL proteinase K) and incubated at 558C for 4 h. Two phenol/chloroform extractions were followed by one chloroform extraction, and DNA was precipitated with cold ethanol. The precipitate was dissolved in 20 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA).
3 PCR was performed with 10 mL of DNA, 2 U of Super Taq (HT Biotechnology, Cambridge, UK), 200 mM deoxynucleotide triphosphate, 100 pmol of each primer and the reaction buffer that was provided with the enzyme. The PCR primers were 5 ′ -TAGACTCGTGGTGGACTT-3 ′ (nt 249-266, sense) and 5 ′ -GTTTAAATGTA 
TACCCAGAGAC-3
′ (nt 837-816, antisense). The programme cycle was 948C for 1 min, 558C for 1 min and 728C for 1 min. To avoid PCR-generated mutations, TaKaRa LA Taq polymerase (Takara Bio Inc., Shiga, Japan), which is capable of proofreading, was used in the PCR (2.5 U per reaction; for verification of the mutations detected). The amplification proceeded for 30 cycles in a Cetus thermal cycler (Perkin-Elmer, Norwalk, CT, USA). A serum sample from a normal subject and an aliquot of water were used as negative controls. Direct sequence analysis was performed on a CEQ 2000 automatic DNA sequencer (Beckman Instruments, Fullerton, CA, USA). The sensitivity and specificity of the assays were tested according to the methods of Chayama et al. 11 and Liaw et al.
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Plasmid construction and site-directed mutagenesis
The pCMV-HBV plasmid was generated by inserting one copy of a greater-than-unit-length HBV genome (3.37 kb, nt 1820-2990, GenBank accession number X02763) into the pRc/CMV vector (Invitrogen, San Diego, CA, USA). The pCMV-YIDD plasmid, containing the rtM204I mutant, was constructed by site-directed mutagenesis as described previously. 3 To construct the plasmid containing the rtS117F single mutation (pCMV-HBV-117F) and rtM204I+rtS117F double-mutations (pCMV-YI DD-117F), PCR-based site-directed mutagenesis was performed using pCMV-HBV and pCMV-YIDD as templates, respectively. The methods were described previously. 3 However, the nucleotide sequences of the complementary primers containing the target mutation, were 5
′ -GATCCT GGAATTAAAGGACAAACGGGC-3 ′ (nt 492-466) and 5 ′ -GCCCGTTTGTCC TTTAATTCCAGGATC-3 ′ (nt 466-492) (the engineered mismatched nucleotides are underlined). After being digested with XbaI and purified by agarose gel electrophoresis, the resulting DNA fragment was used to replace the corresponding XbaI to XbaI fragment (nt 250-1990) in pCMV-HBV or pCMV-YIDD. All plasmids were sequenced on an automatic DNA sequencer (Beckman Instruments Inc.).
Cell culture and plasmid transfection
HepG2 cells, J7 cells, SK-Hep-1 cells and Mahlavu cells (human hepatocellular carcinoma cell lines) were maintained in minimal essential medium containing 10% fetal bovine serum at 378C under 5% CO 2 . Transient transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The transfection efficiency was monitored by co-transfecting a luciferase expression plasmid, pEGFP-C1 (Clontech, Mountain View, CA, USA).
Drug susceptibility assay
To evaluate drug resistance, culture dishes were seeded with 7.5×10 5 HepG2 cells/well. After 48 h, cells were transiently transfected with 5 mg of plasmid using Lipofectamine 2000 (Invitrogen). The four plasmids transfected were pCMV-HBV, pCMV-YIDD, pCMV-HBV-117F and pCMV-YIDD-117F. Twenty-four hours after transfection, cells were provided with fresh medium containing lamivudine (0, 1, 10 or 100 mg/mL). The medium and cells were harvested 2 days later, and HBV DNA levels were quantified using a COBAS TaqMan HBV assay. Replication intermediates of HBV in the cells were also detected by Southern blot analysis.
Quantitative HBsAg assay
HBsAg levels in the culture medium were measured by EIA using the ARCHITECT platform (Abbott Laboratories). The data were calculated against an internal WHO reference standard in IU/mL.
Statistical analysis
Dichotomous data were reported as numbers and percentages, and parametric data were reported as means and standard deviation. Categorical variables were compared using x 2 or Fisher's exact tests, where appropriate. Continuous data were compared using a Student's t-test or the Mann-Whitney U-test, where appropriate. The statistical method used to compare three subgroups was one-way ANOVA and LSD post hoc multiple comparison. All tests were two-tailed, and a P value less than 0.05 was considered statistically significant. All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) for Windows Version 15.0 (SPSS, Chicago, IL, USA).
Results
Clinical characteristics of patients included
In total, 83 lamivudine-resistant patients were included in this study. Of them, 49 had the rtM204I mutation and 34 had the rtM204V mutation. Their demographics are shown in Table 1 . When these two groups were compared, patients with the rtM204I mutation were slightly older (51+12 years versus 46+10 years; P ¼ 0.02). No significant differences were observed for the other clinical variables.
Identification of the rtS117F and rtN124D substitutions as associated mutations of rtM204I
The HBV polymerase gene (reverse transcriptase domain) was amplified and sequenced for each lamivudine-resistant patient. The resulting amino acid sequences were compared, and are shown in Figure 1 HBV sequence was retrieved from GenBank and listed as a reference (genotype B, serotype adw, GenBank accession no. M54923.1). It was found that nine patients in the rtM204I group harboured either the rtS117F or rtN124D mutation but none in the rtM204V group (P ¼ 0.009). The rtL180M mutation was detected in 33 rtM204V carriers and in 19 rtM204I carriers (33/34 versus 19/49; P ¼ 0.0001). The rtV173L mutation was detected in five rtL180M/rtM204V carriers and in two rtM204I carriers (5/33 versus 2/49; P¼ 0.111). The rtL80I mutation was detected in three rtM204V carriers and in nine rtM204I carriers (3/34 versus 9/49; P ¼ 0.343).
Sequence analysis for the emergence of rtS117F, rtN124D and rtM204I mutations during the treatment courses Serial samples were obtained during the treatment course from each patient carrying the rtS117F or rtN124D mutation. The HBV reverse transcriptase sequences derived from these samples were analyzed (Figure 2 ). Tracing the courses of lamivudine therapy in the five patients who harboured the rtS117F mutation, it was found that all five patients (P117-1 to P117-5) developed the rtM204I mutation (P117-2 in 3 months, others in .1 year), followed by emergence of the rtS117F mutation. Tracing the courses of lamivudine therapy in the four patients carrying the rtN124D mutation, it was found that three patients (P124-1, -2 and -4) developed the rtN124D mutation prior to the development of the rtM204I mutation, whereas in patient P124-3, rtN124D and rtM204I mutations were detected at the same time. Therefore, judging from the time mutations emerged, we suspect that rtS117F was a compensatory mutation for the rtM204I mutation. The clinical parameters of these patients were also compared. The clinical data presented in Table 2 were obtained at the timepoints when the rtM204I/rtS117F double mutation, the rtM204I/ rtN124D double mutation and the rtM204I single mutation were first detected during the follow-up. Notably, emergence of the rtS117F mutation resulted in significantly higher serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Nevertheless, prior existence of the rtN124D mutation was associated with significantly higher serum bilirubin levels, higher alpha-fetoprotein (AFP) levels, longer PT values and lower platelet counts. To understand whether the differences had already existed prior to the development of rtM204I/ rtS117F and rtM204I/rtN124D double mutations, the clinical data obtained when only the rtM204I was detected in the rtS117F group and only rtN124D in the latter were reviewed (baseline data). In the rtS117F group, the baseline AST and ALT levels were 55+37 U/L and 85+84 U/L, respectively. No significant difference was found when compared with the other Table 2 . Comparisons of the clinical and virological factors between rtM204I carriers harbouring the rtS117F mutation, the rtN124D mutation and other mutations when the rtM204I/rtS117F double mutations (rtS117F group), rtM204I/rtN124D double mutations (rtN124D group) and rtM204I mutation (others) were first detected Parametric data are expressed as means+SD (range), and dichotomous data are expressed as number (%).
a Patients who had the rtM204I mutation but did not harbour the rtS117F or rtN124D mutation. Comparison between the rtS117F and rtN124D groups. c Comparison between rtS117F and the other mutation group. d Comparison between rtN124D and the others.
Lin et al.
groups. In the rtN124D group, the baseline levels of bilirubin, AFP, platelet and prothrombin time were 1.0+0.3 mg/dL, 5+2 ng/ mL, 208+60×10 3 cells/mL and 12.1+0.7 s, respectively. Again, no significant difference was found when compared with the other groups. Taken together, these data indicated that the elevation of AST and ALT (hepatitis flares) were indeed associated with the emergence of the rtM204I/rtS117F double mutation, and the deterioration of liver function was indeed associated with the emergence of the rtM204I/rtN124D double mutation.
Site-directed mutagenesis and lamivudine susceptibility assays
To determine whether the rtS117F mutation was indeed a compensatory mutation for rtM204I, a site-directed mutagenesis experiment was performed. Plasmids carrying greater-thanunit-length of HBV genomes were constructed. The pCMV-HBV, pCMV-YIDD, pCMV-HBV-117F and pCMV-YIDD-117F plasmids contained wild-type HBV and genomes harbouring rtM204I, rtM117F and rtM204I/rtS117F mutations, respectively. Lamivudine susceptibility tests were performed after plasmid transfection in HepG2 cells (Figure 3) . The replication levels of the wild-type and rtM117F mutant were both significantly susceptible to lamivudine treatment and were suppressed (,0.3-fold) by 100 mg/mL lamivudine. On the other hand, no replication suppression was observed for the rtM204I and rtM204I/rtS117F mutants. Furthermore, an increased replication level was found in the rtM204I mutant. These data indicated that the rtS117F was not a resistance mutation.
The rtS117F mutation exerted a replication compensation effect on the rtM204I mutant Subsequently, we examined whether the rtS117F mutation exerted a compensatory effect on rtM204I replication. Plasmids carrying the wild-type and mutant HBV genomes were transfected into HepG2, Mahlavu, J7 and SK-Hep-1 cells. HBV DNA extracted from the cells and DNA in the medium were quantified using COBAS TaqMan HBV assays. Additionally, intracellular HBV replication intermediates were analyzed by Southern blot and densitometry (Figure 4a) . Compared with the wild-type HBV, the rtM204I mutant showed impaired replication in all cell lines. However, in the rtM204I/rtS117F mutant, the replication efficiency increased to 4.7-fold of the wild-type level in HepG2 cells (Figure 4b) . Similarly, in Mahlavu cells, the replication efficiency of the rtM204I mutant was also significantly impaired, whereas in the rtM204I/rtS117F mutant, the replication was partially recovered. However, no significant compensatory effect was observed in J7 and SK-Hep-1 cells. 
Impaired virion and HBsAg secretion in the rtS117F mutant
The medium to cellular HBV DNA ratios were calculated after being quantified by COBAS TaqMan HBV assays; this represents the secretion efficiency of HBV virions. Strikingly, it was found that virion secretion was significantly impaired in both the rtM204I and rtM204I/rtS117F mutants in both HepG2 and Mahlavu cells (Figure 4c ). Despite the replication compensatory effect in the rtM204I/rtS117F mutant, impairment of virion secretion was observed. Finally, HBsAg levels in the cytoplasm were measured using ARCHITECT ( Figure 5 ). After normalization to the HBV DNA levels, the rtS117F mutant showed a decreased secretion efficiency of HBsAg compared with the wild-type HBV, in both HepG2 and Mahlavu cells. The rtM204I/rtS117F mutant also showed a lower secretion efficiency compared with the rtM204I mutant in these cells.
Discussion
Prolonged or sometimes lifelong antiviral therapy is required in treating patients with chronic HBV infection, to achieve sustained viral suppression. 12 Drug-resistant mutants inevitably emerge in a significant percentage of patients, resulting in virological and biochemical breakthroughs. The development of drug-resistant mutants significantly reduces the efficacy of therapies for The replication intermediates were quantified using densitometry. The levels of WT HBV DNA were assigned as 1.0-fold. Three independent experiments were performed. The mean HBV-DNA levels of the rtM204I and rtM204I/rtS117F mutants were calculated as fold changes relative to wild-type. (c) The HBV DNA levels in the medium and cells were measured using the COBAS TaqMan HBV assay. The ratios were calculated. The ratios of the wild-type HBV were assigned as 1.0-fold. The mean ratios of the rtM204I (white bars) and rtM204I/rtS117F (black bars) mutants were calculated as fold changes of the wild-type ratios. *P, 0.001; **P, 0.01. The increase in HBV DNA level in HepG2 cells for the rtM204I/rtS117F mutant (black bar) was off scale (4.7-fold).
chronic HBV infection: it slows the rate of HBeAg seroconversion, reverses previous gains in liver functional and histological improvement, allows disease progression and increases the risk of hepatic failure. 13 Thus, it is essential to monitor the emergence of antiviral drug resistance during the course of treatment. The major lamivudine resistance mutations in the reverse transcription domain are rtM204V and rtM204I. With these, the accessible surface area between the polymerase and lamivudine is reduced, owing to the presence of the methyl group on the b-branched side chain of valine/isoleucine impinging on the sulphur atom in the unnatural L-oxathiolane ring of lamivudine. 5, 14 In vitro studies have shown that these mutations decrease the susceptibility of HBV to lamivudine more than 100-fold, 15 but no significant difference in the susceptibility changes was detected between the two mutants.
Enomoto et al. 16 retrospectively studied clinical characteristics in 30 patients with YMDD variants during lamivudine monotherapy for at least 6 months. There was no significant difference in the clinical characteristics (either at the baseline or at the time of drug resistance) between 18 patients with the rtM204I mutation and 12 patients with rtM204V. In our study, it was found that the 49 patients with the rtM204I mutation were significantly older than the 34 patients with rtM204V mutant (P ¼ 0.02). At this time, it is unclear whether this age-related difference is indeed attributable to the virological or clinical consequences of the rtM204I mutant, or if it is merely caused by statistical bias resulting from multiple comparisons. Further studies using an independent cohort of patients are needed to verify this finding.
HBV carrying primary drug resistance mutations replicates less efficiently in vitro, but accumulation of additional or compensatory mutations can restore viral replication and fitness. 13 This study aimed at exploring unrecognized compensatory mutations in lamivudine-resistant strains. It was found that in five rtM204I variants additionally harbouring the rtS117F mutation, clinical hepatitis flares occurred with increased ALT and AST levels. Site-directed mutagenesis experiment showed that in HBV carrying rtM204I/rtS117F double mutations, replication efficiencies were partially or fully restored in hepatoma cell lines. The drug susceptibility test indicated that the rtS117F mutation was not a resistance mutation. These data clearly indicate that the rtS117F mutation is a compensatory mutation for the rtM204I mutation. On the other hand, we accidently discovered that prior existence of the rtN124D mutation in four patients was associated with the development of liver decompensation upon emergence of the rtM204I mutation. To our knowledge, the finding that a prior existing mutation can predict development of liver decompensation upon emergence of drug resistance has never been reported. The molecular mechanism of this novel finding is unclear at this time. Site-directed mutagenesis experiments may provide clues to solve this puzzle.
The most common compensatory mutation associated with lamivudine resistance is rtL180M. This mutation by itself did not confer resistance to lamivudine but could restore the replication deficiency of rtM204V. 17 Moreover, the rtV173L mutation has been reported in 8% of immunocompetent, lamivudine-resistant, chronic hepatitis B patients (5/59), 19% of lamivudine-resistant liver transplant recipients (23/122) and 23% of HIV co-infected patients (8/35) in whom lamivudine therapy has failed. 18 In vitro, the rtV173L mutation restored the replication yield of HBV harbouring the rtL180M/rtM204V mutant but did not change its susceptibility to lamivudine. On the other hand, the rtN124D and rtS117F mutations were detected exclusively in patients carrying the rtM204I mutation. The rtL180M and rtV173L mutations were compensatory mutations for rtM204V. In some previous reports, the rtL180M mutation was also found in patients with the rtM204I mutation. In our study, the rtL180M mutation was detected in 33 rtM204V carriers and in 19 rtM204I carriers (33/ 34 versus 19/49; P ¼0.0001). However, the replication compensatory effect for rtM204I had not been characterized in vitro. Interestingly, the rtL180M mutation was found in 3 out of 5 patients carrying the rtS117F/rtM204I mutation (Figure 1a ). It could be speculated that in these three patients, viral replication was much less efficient, and therefore two secondary mutations (rtS117F and rtL180M) were selected to compensate for the replication deficiency. Similarly, the rtV173L mutation was detected in two rtM204I patients, and one of them also carried the rtL180M mutation. Furthermore, the rtL80I mutation was detected in two patients carrying the rtS117F/rtM204I mutation ( Table 2) . Taken together, we speculate that the rtL80I, rtS117F, rtV173L and rtL180M mutations all serve as compensatory mutations in the rtM204I mutant; in some patients, more than one compensatory mutation was needed for effective replication compensation.
Owing to the overlap of the S and polymerase genes, drug-resistant mutations occur not only in the polymerase WT rtS117F rtM204I rtM204I/rtS117F Figure 5 . Quantification of the secreted HBsAg. HepG2 and Mahlavu cells were transiently transfected with plasmids containing the wild-type (WT), rtS117F, rtM204I or rtM204I/rtS117F HBV genomes. HBsAg in the medium was quantified using the ARCHITECT kit. The levels of HBsAg were normalized to the cellular HBV DNA levels.
gene but also in the S gene, resulting in the emergence of surface protein mutants. This kind of mutation is defined as the 'first type' of antiviral drug-associated S gene mutants (ADASMs). 19 These S gene mutations can lead to three consequences in the pre-S/S reading frame: amino acid substitutions in the pre-S/S proteins (including the large, middle and small S proteins); nonsense mutations leading to truncation of pre-S/S proteins; and silent mutations. The resulting changes in HBsAg may influence viral replication and antibody recognition. 13 Some mutations could impair secretion of HBsAg and viral particles, or increase oncogenic potential in xenograft. 20, 21 Although the rtS117F mutant generated only a silent mutation in the S gene, in our studies the rtS117F or rtM204V/rtS117F mutants also inhibited HBsAg and virion secretion. Retention and accumulation of virion/HBsAg in the cells likely results in liver cell damage and thus leads to hepatitis exacerbation, as supported by our clinical data. However, the mechanism by which secretion failure of virion/HBsAg could occur in the absence of pre-S/S protein mutation is unknown at this time. Our data suggest that amino acid substitution in the reverse transcriptase itself could lead to secretion failure of virion/HBsAg. It can be speculated that alteration of polymerase function could affect virion maturation, leading to retention of immature virions and HBsAg on the ER membrane.
In summary, we have discovered a novel compensatory mutation, rtS117F, which emerged and restored replication efficiency of the rtM204I mutant after prolonged lamivudine therapy. Clinically, emergence of the rtS117F mutation was associated with hepatitis flares. Additionally, prior existence of the rtN124D mutation was associated with liver decompensation upon development of the rtM204I mutation. In patients receiving prolonged lamivudine treatment, monitoring of the rtS117F and rtN124D mutations is recommended.
